ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > ProMIS initiates commercialization of COVID-19 assay

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon May 25, 2021 8:27am

109 Views

Post# 33258768

RE:RE:ProMIS initiates commercialization of COVID-19 assay

I think PMN was forced to make some type of announcement on the serology test to meet their requirements of disclosure for material information, especially with the BC lab releasing info on the test and appearing to make it available fornthe public . I PERSONALLY think that we will be getting more news releases from PMN ,but now it looks like ImmuSAFE is ready to officially reveal their test and it will fall in place with Immunity Passports program....there is so much more that we need to know...

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario